Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Head and Neck Cancer
Tafinlar plus Mekinist Combination Approved for Pediatric Low-Grade Glioma with BRAFᵛ⁶⁰⁰ᴱ Mutation
FDA Approvals, News & Updates
,
Head and Neck Cancer
April 2023, Vol 14, No 2
On
March 16, 2023
, the FDA approved dabrafenib (Tafinlar; Novartis) in combination with trametinib (Mekinist; Novartis) for the treatment of pediatric patients aged ≥1 year with low-grade glioma that harbors a
BRAF
V600E
mutation and who require systemic therapy.
Read Article
New Saliva Test Can Detect HPV-Associated Head and Neck Cancer
By
Wayne Kuznar
Head and Neck Cancer
October 2021, Vol 12, No 5
Oropharyngeal cancer, which can develop at the base of the tongue, tonsils, and the middle part of the throat, is primarily caused by human papillomavirus (HPV) infection, the most common sexually transmitted virus and infection in the United States. Over the past 2 decades, cases of HPV-positive oropharyngeal squamous-cell carcinoma (OPSCC) have been increasing at an alarming rate among men in the United States. According to the American Cancer Society, approximately 54,000 cases of oropharyngeal and oral cavity cancer will be diagnosed in the United States in 2021, and more than 10,000 individuals will die from the disease. OPSCC is often diagnosed at an advanced stage, resulting in increased mortality and morbidity.
Read Article
November 4, 2019 — Oncology News & Updates
Financial Toxicity
,
Genomic Testing
,
Head and Neck Cancer
,
In the News
,
Leukemia
Web Exclusives
Read Article
Oral Cancer and Sex in the Era of HPV Infection
By
Meg Barbor, MPH
Head and Neck Cancer
October 2019, Vol 10, No 5
San Francisco, CA—The increasing rate of infection with the human papillomavirus (HPV) in the United States has changed the field of head and neck cancer, or oral cancer, and HPV infection now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising, so is patients’ curiosity about what sets this cancer apart from other malignancies.
Read Article
Systemic Therapy Wins One, Loses One in Head and Neck Cancer
By
Charles Bankhead
Head and Neck Cancer
March 2014, Vol 5, No 2
Scottsdale, AZ—The addition of chemotherapy to irradiation proved superior to accelerated radiotherapy without systemic therapy in a randomized trial of patients with advanced head and neck cancer.
Read Article
Outpatient Chemoradiation Regimen Matches Inpatient Care Outcomes, at Lower Costs
By
Charles Bankhead
Head and Neck Cancer
March 2014, Vol 5, No 2
Scottsdale, AZ—Definitive chemoradiation with single-agent outpatient chemotherapy for head and neck cancer led to disease control and survival equivalent to that of inpatient multi-agent therapy, at an annualized savings of almost $650,000, according to results of a small randomized trial presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium.
Read Article
Lymphedema a Common Problem in Head and Neck Cancer
By
Alice Goodman
Head and Neck Cancer
September 2013, Vol 4, No 7
Berlin, Germany—Although little is known about the prevalence of lymphedema in patients with head and neck cancer, a series of studies showed that 75% of patients with head and neck cancer have problematic lymphedema internally and externally.
Read Article
Gene Expression May Simplify Search for Effective Therapy in Head and Neck Cancer
By
Charles Bankhead
Head and Neck Cancer
,
Personalized Medicine
May 2013, Vol 4, No 4
Therapeutic development in head and neck cancer could eventually hone in on a handful of gene-expression patterns and signaling pathways that can identify a few discrete subtypes of the disease, data from The Cancer Genome Atlas suggest.
Read Article
Use of Intensity-Modulated Radiotherapy Increasing and Costly in the Management of Head and Neck Cancers, but Value Unknown
Head and Neck Cancer
September 2012, Vol 3, No 6
Toronto, Canada—The popularity of intensity-modulated radiotherapy (IMRT) for head and neck cancer has climbed rapidly in recent years. However, the extra cost associated with this treatment modality may not equate with improved value, according to researchers from the University of California at Los Angeles (UCLA), who presented their analysis at the 2012 International Conference on Head and Neck Cancer.
Read Article
New Calculator Shows Financial Impact of Poor Quality of Care to an Institution, and How to Correct It
Head and Neck Cancer
,
Quality Care
,
Policies & Guidelines
September 2012, Vol 3, No 6
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma